

2021 年 学術報告

【発表論文】

(主に当科で行われたもの)

1. Nishikubo M, Shimomura Y, Hiramoto N, Sawamura N, Yamaguchi T, Hara S, Ishikawa T. Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report. *BMC Nephrol*. 2021 May 12;22(1):175.
2. Shimomura Y, Hara M, Yamamoto H, Uchida N, Kawakita T, Ashida T, Takada S, Ikeda T, Morishige S, Maruyama Y, Wake A, Ichinohe T, Fukuda T, Takanashi M, Atsuta Y, Ishikawa T. Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies. *Bone Marrow Transplant*. 2021 Jul;56(7):1691-1699.
3. Imoto H, Yoshioka S, Hiramoto N, Morita-Fujita M, Yamashita D, Ishikawa T. Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for systemic Epstein-Barr virus-positive T-cell lymphoma of childhood. *Bone Marrow Transplant*. 2021 Jul;56(7):1743-1745.
4. Kamijo K, Shimomura Y, Yamashita D, Ishikawa T. A Case of Tyrosine Kinase Inhibitor-Induced Bone Marrow Aplasia That Was Successfully Treated with Allogeneic Hematopoietic Stem Cell Transplantation. *Case Rep Oncol*. 2021 Jul 19;14(2):1139-1143.
5. Wada F, Hiramoto N, Yamashita D, Hara S, Furukawa Y, Ishii J, Nagata K, Nannya Y, Ogawa S, Ishikawa T. Dramatic response to encorafenib in a patient with Erdheim-Chester disease harboring the BRAF^{V600E} mutation. *Am J Hematol*. 2021 Aug 1;96(8):E295-E298.
6. Shimomura Y, Hara M, Hirabayashi S, Kondo T, Mizuno S, Uchida N, Mukae J, Kawakita T, Fukuda T, Kanda Y, Ota S, Ozawa Y, Eto T, Maruyama Y, Tanaka M, Nakano N, Kimura T, Ichinohe T, Atsuta Y, Yanada M. Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status. *Bone Marrow Transplant*. 2021 Sep;56(9):2302-2304.
7. Yamada C, Shimomura Y, Kamijyo K, Kanda-Kato M, Yoshioka S, Yamashita D, Ishikawa T. BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy. *Intern Med*. 2021 Oct 1;60(19):3149-3153.
8. Shimomura Y, Hara M, Konuma T, Itonaga H, Doki N, Ozawa Y, Eto T, Uchida N, Aoki J, Kato J, Onishi Y, Takahashi S, Fukushima K, Nakamae H, Kawakita T, Tanaka J, Fukuda T, Atsuta Y, Ishikawa T, Ishiyama K. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. *Bone Marrow*

Transplant. 2021 Oct;56(10):2510-2517.

9. Wada F, Shimomura Y, Yabushita T, Yamashita D, Ohno A, Imoto H, Maruoka H, Hara S, Ishikawa T. CD38 expression is an important prognostic marker in diffuse large B-cell lymphoma. *Hematol Oncol*. 2021 Oct;39(4):483-489.

(共同研究)

1. Yoshida S, Fujimoto A, Fukushima K, Ando M, Irie K, Hirano T, Miyasaka M, Shimomura Y, Ishikawa T, Ikesue H, Muroi N, Hashida T, Sugioka N. Population pharmacokinetics of tacrolimus in umbilical cord blood transplant patients focusing on the variation in red blood cell counts. *J Clin Pharm Ther*. 2021 Feb;46(1):190-197.
2. Yanada M, Konuma T, Mizuno S, Saburi M, Shinohara A, Tanaka M, Marumo A, Sawa M, Uchida N, Ozawa Y, Onizuka M, Yoshioka S, Nakamae H, Kondo T, Kimura T, Kanda J, Fukuda T, Atsuta Y, Nakasone H, Yano S. Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. *Bone Marrow Transplant*. 2021 Feb;56(2):387-394.
3. Harada K, Fuji S, Seo S, Uchida N, Kawakita T, Yano S, Ozawa Y, Yoshioka S, Onishi Y, Noguchi Y, Onizuka M, Matsushashi Y, Kimura T, Ichinohe T, Atsuta Y, Transplant Complications Working Group of the Japan Society for Hematopoietic Cell Transplantation, GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation, Terakura S, Nakasone H. Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2021 Feb;56(2):400-410.
4. Sugita J, Kamimura T, Ishikawa T, Ota S, Eto T, Kuroha T, Miyazaki Y, Kumagai H, Matsuo K, Akashi K, Taniguchi S, Harada M, Teshima T. Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. *Bone Marrow Transplant*. 2021 Mar;56(3):596-604.
5. Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, Choi I, Humphrey K, Kim SY, Okubo S, Ogawa N, Nishimura Y, Salem AH, Maruyama D. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. *Int J Hematol*. 2021 Mar;113(3):370-380.
6. Iida S, Ishikawa T, Min CK, Kim K, Yeh SP, Usmani SZ, Mateos MV, Nahi H, Heuck C, Qin X, Parasrampur DA, Gries KS, Qi M, Bahlis N, Ito S. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study. *Ann Hematol*. 2021 Apr;100(4):1065-1077.
7. Fujikura K, Yamashita D, Yoshida M, Ishikawa T, Itoh T, Imai Y. Cytogenetic

complexity and heterogeneity in intravascular lymphoma. *J Clin Pathol*. 2021 Apr;74(4):244-250.

8. Konuma T, Kanda J, Yamasaki S, Harada K, Shimomura Y, Terakura S, Mizuno S, Uchida N, Tanaka M, Doki N, Ozawa Y, Nakamae H, Sawa M, Matsuoka KI, Morishige S, Maruyama Y, Ikegame K, Kimura T, Kanda Y, Ichinohe T, Atsuta Y, Yanada M. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission. *Transplant Cell Ther*. 2021 Apr;27(4):334.e1-334.e11.
9. Ochi Y, Yoshida K, Huang YJ, Kuo MC, Nannya Y, Sasaki K, Mitani K, Hosoya N, Hiramoto N, Ishikawa T, Branford S, Shanmuganathan N, Ohyashiki K, Takahashi N, Takaku T, Tsuchiya S, Kanemura N, Nakamura N, Ueda Y, Yoshihara S, Bera R, Shiozawa Y, Zhao L, Takeda J, Watatani Y, Okuda R, Makishima H, Shiraishi Y, Chiba K, Tanaka H, Sanada M, Takaori-Kondo A, Miyano S, Ogawa S, Shih LY. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. *Nat Commun*. 2021 May 14;12(1):2833.
10. Kawai H, Ando K, Maruyama D, Yamamoto K, Kiyohara E, Terui Y, Fukuhara N, Miyagaki T, Tokura Y, Sakata-Yanagimoto M, Igarashi T, Kuroda J, Fujita J, Uchida T, Ishikawa T, Yonekura K, Kato K, Nakanishi T, Nakai K, Matsunaga R, Tobinai K. Phase 2 study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. *Cancer Sci*. 2021 Jun;112(6):2426-2435.
11. Fukushima T, Shimomura Y, Nagaya S, Morishita E, Kawakami O. A Case of Treatment With Dabigatran for Cerebral Venous Thrombosis Caused by Hereditary Protein C Deficiency. *Cureus*. 2021 Jun 6;13(6):e15473.
12. Hosen N, Yoshihara S, Takamatsu H, Ri M, Nagata Y, Kosugi H, Shimomura Y, Hanamura I, Fuji S, Minauchi K, Kuroda J, Suzuki R, Nishimura N, Uoshima N, Nakamae H, Kawano Y, Mizuno I, Gomyo H, Suzuki K, Ozaki S, Nakamura S, Imai Y, Kizaki M, Negoro E, Handa H, Iida S. Expression of activated integrin $\beta 7$ in multiple myeloma patients. *Int J Hematol*. 2021 Jul;114(1):3-7.
13. Terui Y, Rai S, Izutsu K, Yamaguchi M, Takizawa J, Kuroda J, Ishikawa T, Kato K, Suehiro Y, Fukuhara N, Ohmine K, Goto H, Yamamoto K, Kanemura N, Ueda Y, Ishizawa K, Kumagai K, Kawasaki A, Saito T, Hashizume M, Shibayama H. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. *Cancer Sci*. 2021 Jul;112(7):2845-2854.
14. Hashimoto A, Tanaka Y, Ishikawa T, Shinzato I. Successful treatment of acute promyelocytic leukemia in a patient under hemodialysis with arsenic trioxide. *Clin Case Rep*. 2021 Jul 23;9(7):e04417.

15. Yamashita K, Shimomura Y, Ikeshue H, Muroi N, Yoshimoto A, Hashida T. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of *Pneumocystis pneumonia* in HIV uninfected patients undergoing hemodialysis: a retrospective observational study *BMC Infect Dis*. 2021 Jul 8;21(1):664.
16. Ikeshue H, Mouri M, Tomita H, Hirabatake M, Ikemura M, Muroi N, Yamamoto S, Takenobu T, Tomii K, Kawakita M, Katoh H, Ishikawa T, Yasui H, Hashida T. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. *Support Care Cancer*. 2021 Aug;29(8):4763-4772.
17. Doki N, Toyosaki M, Shiratori S, Osumi T, Okada M, Kawakita T, Sawa M, Ishikawa T, Ueda Y, Yoshinari N, Nakahara S An Open-label, Single-arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease. *Transplant Cell Ther*. 2021 Oct;27(10):867.e1-867.e9.
18. Hosono N, Yokoyama H, Aotsuka N, Ando K, Iida H, Ishikawa T, Usuki K, Onozawa M, Kizaki M, Kubo K, Kuroda J, Kobayashi Y, Shimizu T, Chiba S, Nara M, Hata T, Hidaka M, Fujiwara SI, Maeda Y, Morita Y, Kusano M, Lu Q, Miyawaki S, Berrak E, Hasabou N, Naoe T. Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia. *Int J Clin Oncol*. 2021 Nov;26(11):2131-2141.
19. Kurosawa S, Shimomura Y, Itonaga H, Najima Y, Kobayashi T, Ozawa Y, Kanda Y, Kako S, Kawakita T, Matsuoka KI, Maruyama Y, Ota S, Nakazawa H, Imada K, Kanda J, Fukuda T, Atsuta Y, Aoki J. Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis. *Bone Marrow Transplant*. 2021 Dec;56(12):3008-3015.

【学会発表】

(筆頭著者が当科のもの)

1. 小久保 結未, 西久保 雅司, 岡田 直樹, 井本 寛東, 山本 隆介, 平本 展大, 石川 隆之, 澤村 直彦, 山口 貴子, 原 重雄 高度蛋白尿を偶発的に発見し、薬剤中止により軽快した Gemcitabine による薬剤性血栓性微小血管症(DI-TMA)の 1 例 第 231 回日本内科学会近畿地方会 2021/3/13
2. 松本 絢子 下村 良充 上條 公守 和田 典也 吉岡 聡 松下 章子 石川 隆之 免疫チェックポイント阻害薬による血小板減少を来した二例 第 115 回近畿血液学地方会 2021/6/5
3. 上條公守, 和田典也, 下村良充, 吉岡 聡, 松下章子, 石川隆之 体動困難のために救急搬送となりビタミン B12 欠乏症の診断に至った 1 例 第 232 回日本内科学会近畿地

方会 2021/6/26

4. 西久保 雅司、平本 展大、井本 寛東、山本 隆介、下村 良充、丸岡 隼人、石川 隆之
Patient's characteristics and molecular MRD status and outcome in NPM1-mutated AML
第 83 回日本血液学会総会
5. 和田 典也、下村 良充、藪下 知宏、山下 大祐、大野 彩、井本 寛東、丸岡 隼人、原 重雄、石川 隆之
CD38 expression is an important prognostic marker in diffuse large B-cell lymphoma 第 83 回日本血液学会総会 2021/9/24
6. 上條 公守、下村 良充、岡田 直樹、和田 典也、西久保 雅司、井本 寛東、山本 隆介、平本 展大、吉岡 聡、米谷 昇、松下 章子、山下 大祐、原 重雄、石川 隆之
Clinical characteristics and outcomes of duodenal-type follicular lymphoma: a single center analysis 第 83 回日本血液学会総会 2021/9/25
7. 久保茂世、中川大志、上條公守、下村良充、山本隆介、永井雄也、平本展大、吉岡聡、米谷昇、石川隆之
当院の急性骨髄性白血病に対するベネトクラクス+アザシチジンの使用経験 第 116 回近畿血液学地方会 2021/11/27
8. 山田智彦、平本展大、山本隆介、米谷昇、石川隆之
クローン性造血に由来した芽球性形質細胞様樹状細胞腫瘍と骨髄異形成症候群を合併した一例 第 116 回近畿血液学地方会 2021/11/27
9. 光行智司、西久保雅司、岡田直樹、井本寛東、山本隆介、平本展大、石川隆之、山下大祐、丸岡隼人
抗MAG抗体関連ニューロパチーを合併したMYD88変異陽性のDLBCL 第 116 回近畿血液学地方会 2021/11/27
10. 馬場 晟弥、中川 大志、久保 茂世、上條 公守、下村 良充、永井 雄也、吉岡 聡、石川 隆之
エルトロンボバグが奏功した COVID-19 に伴う免疫性血小板減少症 第 234 回日本内科学会近畿地方会 2021/12/4
11. Fumiya Wada, Junya Kanda, Satoshi Yoshioka, Takayuki Ishikawa, Takashi Akasaka, Yasunori Ueda, Hirokazu Hirata, Yasuyuki Arai, Kazuhiro Yago, Naoyuki Anzai, Mitsumasa Watanabe, Takashi Ikeda, Akihito Yonezawa, Kazunori Imada, Mitsuru Itoh, Toshiyuki Kitano, Tomoharu Takeoka, Masakatsu Hishizawa, Masaharu Nohgawa, Nobuyoshi Arima, Kosuke Asagoe, Tadakazu Kondo, Akifumi Takaori-Kondo. Single Cord Blood Transplantation Versus HLA-Haploidentical Related Donor Transplantation Using Post-Transplant Cyclophosphamide in Patients with Hematological Malignancies
62 nd Annual Meeting and Exposition of American Society of Hematology 2021/12/12
12. Yoshimitsu Shimomura, Tomotaka Sobue, Shigeki Hirabayashi, Tadakazu Kondo, Shohei Mizuno, Junya Kanda, Takahiro Fujino, Keisuke Kataoka, Naoyuki Uchida, Tetsuya Eto, Shigesaburo Miyakoshi, Masatsugu Tanaka, Toshiro Kawakita, Hisayuki Yokoyama, Noriko Doki, Kaito Harada, Atsushi Wake, Shuichi Ota, Satoru Takada, Satoshi Takahashi, Takafumi Kimura, Makoto Onizuka, Takahiro Fukuda, Yoshiko Atsuta,

Masamitsu Yanada. Comparing Single Cord Blood Transplantation and Matched Related Donor Transplantation in Non-Remission Acute Myeloid Leukemia 62 nd Annual Meeting and Exposition of American Society of Hematology 2021/12/11

(主な共同研究)

1. 山下 大祐、吉本 明弘、石川 隆之、原 重雄 A clinicopathological analysis of primary renal lymphoma diagnosed by kidney biopsy 第 83 回日本血液学会総会 2021/9/23
2. 越智 陽太郎、吉田 健一、南谷 泰仁、佐々木 光、三谷 絹子、細谷 紀子、平本 展大、石川 隆之、大屋敷 一馬、高橋 直人、高久 智生、土屋 俊、兼村 信宏、中村 信彦、上田 恭典、吉原 哲、塩澤 裕介、趙 蘭英、竹田 淳恵、綿谷 陽作、奥田 瑠璃花、牧島 秀樹、白石 友一、千葉 健一、田中 洋子、真田 昌、高折 晃史、宮野 悟、Lee-Yung Shih、小川 誠司 Clonal evolution and clinical impact of genetic lesions in blast crisis of chronic myeloid leukemia 第 83 回日本血液学会総会 2021/9/23
3. 南谷 泰仁、Tobiasson Magnus、佐藤 信也、Bernard Elsa、大竹 茂樹、竹田 淳恵、趙 蘭英、日下部 学、柴田 悠平、中村 信彦、渡邊 瑞希、平本 展大、塩澤 裕介、白石 友一、牧島 秀樹、中川 正宏、田口 正剛、木口 亨、大屋敷 一馬、石川 隆之、高折 晃史、鶴見 寿、笠原 千嗣、千葉 滋、直江 知樹、宮野 悟、Papaemanuil Elli、宮崎 泰司、Lindberg Eva、小川 誠司 Post-azacitidine clone size predicts long-term clinical outcome of patients with MDS and AML 第 83 回日本血液学会総会
4. 竹田 淳恵、吉田 健一、依田 成玄、南谷 泰仁、Leeyung Shih、越智 陽太郎、白石 友一、Cassandra Kerr、永田 安伸、北野 俊行、半下石 明、石山 謙、鶴見 寿、宮崎 泰司、平本 展大、石川 隆之、中川 正宏、高折 晃史、千葉 滋、中澤 英之、Mingchung Kuo、片岡 圭亮、佐伯 龍之介、真田 昌、臼杵 憲祐、宮脇 修一、宮野 悟、Jaroslav Maciejewski、牧島 秀樹、小川 誠司 EPOR/JAK/STAT pathway is a promising therapeutic target in acute erythroid leukemia 第 83 回日本血液学会総会 2021/9/24
5. 福島 健太郎、白鳥 聡一、大西 康、土岐 典子、後藤 辰徳、岡田 昌也、中前 博久、前田 嘉信、加藤 光次、石川 隆之、近藤 忠一、豊崎 誠子、池田 宇次、谷口 修一、岩本 章子、島田 文香、Tommaso Stefanelli、Norbert Hollaender、豊嶋 崇徳 Ruxolitinib vs best available therapy in steroid-refractory cGvHD: REACH3 in Japanese patients 第 83 回日本血液学会総会
6. Elsa Bernard, Heinz Tuechler, Peter L. Greenberg, Robert P. Hasserjian, Juan Arango Ossa, Yasuhito Nannya, Sean M Devlin, Maria Creignou, Philippe Pinel, Lily Monnier, Juan S Medina-Martinez1, Yesenia Werner, Martin Jädersten, Ulrich Germing, Guillermo Sanz, Arjan A. Van de Loosdrecht, Olivier Kosmider, Matilde Y Follo, Felicitas R Thol, Lurdes Zamora, Ronald Feitosa Pinheiro, Andrea Pellagatti, Harold Elias, Detlef Haase, Christina Ganster, Lionel Ades, Magnus Tobiasson, Matteo G. Della Porta, Akifumi Takaori-Kondo, Takayuki Ishikawa, Shigeru Chiba, Senji Kasahara, Yasushi Miyazaki,

Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio Pires de Souza Santos, Jacqueline Boultonwood, Ioannis Kotsianidis, Valeria Santini, Francesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Kazuma Ohyashiki, Carlo Finelli, Maria Teresa Teresa Voso, Lee-Yung Shih, Michaela Fontenay, Joop H. Jansen, José Cervera, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Luca Malcovati, Mario Cazzola, Seishi Ogawa, Eva Hellström-Lindberg, Elli Papaemmanuil. Molecular International Prognosis Scoring System for Myelodysplastic Syndromes. 62 nd Annual Meeting and Exposition of American Society of Hematology 2021/12/11

7. June Takeda, Kenichi Yoshida, Masahiro Marshall Nakagawa, Yasuhito Nannya, Akinori Yoda, Daisuke Morishita, Ryunosuke Saiki, Kenichi Chiba, Hiroko Tanaka, Yuichi Shiraishi, Ming-Chung Kuo, Cassandra M Kerr, Yasunobu Nagata, Nobuhiro Hiramoto, Akira Hangaishi, Hideyuki Nakazawa, Ken Ishiyama, Satoru Miyano, Shigeru Chiba, Yasushi Miyazaki, Toshiyuki Kitano, Kensuke Usuki, Nobuo Sezaki, Hisashi Tsurumi, Shuichi Miyawaki, Jaroslaw P. Maciejewski, Takayuki Ishikawa, Kazuma Ohyashiki, Arnold Ganser, Michael Heuser, Felicitas R Thol, Lee-Yung Shih, Akifumi Takaori-Kondo, Hideki Makishima, Seishi Ogawa. EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia 62 nd Annual Meeting and Exposition of American Society of Hematology 2021/12/13
8. Kenshi Suzuki, Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Daisuke Iguchi, Koji Izutsu. Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia. Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia 62 nd Annual Meeting and Exposition of American Society of Hematology 2021/12/11
9. Shuhei Kurosawa, Yoshimitsu Shimomura, Hidehiro Itonaga, Yuho Najima, Takeshi Kobayashi, Yukiyasu Ozawa, Yoshinobu Kanda, Shinichi Kako, Toshiro Kawakita, Ken-Ichi Matsuoka, Yumiko Maruyama, Shuichi Ota, Hideyuki Nakazawa, Kazunori Imada, Takafumi Kimura, Junya Kanda, Takahiro Fukuda, Yoshiko Atsuta, Ken Ishiyama. Comparison of Myeloablative Versus Reduced-Intensity Fludarabine/Busulfan Regimen in Patients with Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Stem Cell Transplantation 62 nd Annual Meeting and Exposition of American Society of Hematology 2021/12/13